Skip to main content

Advertisement

SpringerLink
Log in

Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Objective

This study investigated the inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric cancer cell line (MGC-803).

Methods

Cultured MGC-803 human gastric cancer cells were treated with bevacizumab in combination with chemotherapy treatment in different time sequences. The effects on cell growth inhibition were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell cycle distribution and the rate of cell apoptosis were determined by propidium iodide staining followed by flow cytometry.

Results

Drug administration for different time sequences significantly inhibited the growth of MGC-803 cells. Based on group comparisons (P < 0.01), the effect of 24 h bevacizumab treatment prior to combination 5-fluorouracil and cisplatin (FP) was the strongest (F = 241.313, 246.856, all P values <0.001). Treating MGC-803 cells with bevacizumab for 24 h before combination FP induced significant G2/M phase arrest (F = 231.991, P < 0.001) and significantly increased gastric cancer cell apoptosis. Bevacizumab in combination with chemotherapy significantly inhibits the proliferation of MGC-803 gastric cancer cells.

Conclusions

The mechanism may be related to cell cycle arrest at S phase and the induction of apoptosis in MGC-803 gastric cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Casaretto L, Sousa PL, Mari JJ (2006) Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res 39:431–440

    Article  CAS  PubMed  Google Scholar 

  2. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  CAS  PubMed  Google Scholar 

  3. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlledtrial. Lancet 376:687–697

    Article  CAS  PubMed  Google Scholar 

  4. Aoyagi K, Kouhuji K, Kizaki J et al (2014) Molecular targeting to treat gastric cancer. World J Gastroenterol 20:13741–13755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thiel A, Ristimäki A (2015) Targeted therapy in gastric cancer. APMIS 123:365–372

    Article  CAS  PubMed  Google Scholar 

  6. Booy EP, Johar D, Maddika S et al (2006) Monoclonal and bispecific antibodies as novel therapeutics. Arch Immunol Ther Exp (Warsz) 54:85–101

    Article  CAS  Google Scholar 

  7. Jain VK, Hawkes EA, Cunningham D (2011) Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 10:245–257

    Article  CAS  PubMed  Google Scholar 

  8. Aprile G, Ongaro E, Del Re M et al (2015) Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: a critical insight. Crit Rev Oncol Hematol 95:165–178

    Article  PubMed  Google Scholar 

  9. Han K, Jin J, Maia M et al (2014) Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST Phase III trial. The AAPS J 16:1056–1063

    Article  PubMed  Google Scholar 

  10. Browder T, Butterfield CE, Kräling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886

    CAS  PubMed  Google Scholar 

  11. Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501–7506

    CAS  PubMed  Google Scholar 

  12. Ramalingam SS, Dahlberg SE, Langer CJ et al (2008) Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60–65

    Article  CAS  PubMed  Google Scholar 

  13. Peng XC, Qiu M, Wei M et al (2012) Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemother Pharmacol 69:239–246

    Article  CAS  PubMed  Google Scholar 

  14. Xu WJ, Huang C, Wang J et al (2011) Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states. Chin Med J (Engl) 124:2883–2889

    CAS  Google Scholar 

  15. Yuan ZY, Liu XB, Zhuang HQ et al (2011) Radiosensitizing effects of h-R3 with different time series of administration on human lung cancer cells expressing various EGFR levels. Chin J Clin Oncol 38:1019–1023

    CAS  Google Scholar 

  16. Lei X, Lv X, Liu M et al (2012) Thymoquinone inhibits growth and augments 5-fluorouracil induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun 417:864–868

    Article  CAS  PubMed  Google Scholar 

  17. Zheng YB, Xiao GC, Tong SL et al (2015) Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3 K/Akt and STAT3 signaling. World J Gastroenterol 21:7197–7207

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Kim MK, James J, Annunziata CM (2015) Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer 15:196

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bogusz J, Majchrzak A, Mędra A et al (2013) Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (online) 67:107–118

    Article  Google Scholar 

  20. Carneiro A, Falcão M, Pirraco A et al (2009) Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88:522–527

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei, China

    Y. Lv, L. Song, L. Chang, Y. Liu, X. Zhou & W. Liu

  2. Department of Epiderniology, Hebei Medical University, Shijiazhuang, 050011, Hebei, China

    X. Zhang

  3. Department of Physiology, Hebei Medical University, Shijiazhuang, 050011, Hebei, China

    Q. Li

Authors
  1. Y. Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. X. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Liu.

Ethics declarations

Conflicts of interest

All of the authors declare that they have no conflicts of interest regarding this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lv, Y., Song, L., Chang, L. et al. Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line. Ir J Med Sci 186, 275–280 (2017). https://doi.org/10.1007/s11845-016-1471-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-016-1471-1

Keywords

Search

Navigation